Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re-analysis of a meta-analysis

Shouhao Zhou; Chan Shen

doi:10.1002/jgh3.12856

Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re-analysis of a meta-analysis

JGH Open. 2023 Jan 24;7(2):163-164. doi: 10.1002/jgh3.12856. eCollection 2023 Feb.

Authors

Shouhao Zhou^{1

2}, Chan Shen^{1

2

3}

Affiliations

¹ Department of Public Health Sciences, College of Medicine Pennsylvania State University Hershey Pennsylvania USA.
² Penn State Cancer Institute Pennsylvania State University Hershey Pennsylvania USA.
³ Department of Surgery, College of Medicine Pennsylvania State University Hershey Pennsylvania USA.

Abstract

We identified analytic limitations in a recent meta-analysis and re-examined the efficacy and safety associated with immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma (HCC) compared with standard therapies. Our findings mostly contradict conclusions from the previous study, suggesting the need for continuing the investigation of ICIs in HCC with additional clinical evidence.

Keywords: Bayesian statistics; immune checkpoint inhibitors; meta‐analysis; predictive intervals; unresectable hepatocellular carcinoma.